Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/745—Blood coagulation or fibrinolysis factors
  • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
• • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
  • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
  • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
  • F16L55/00—Devices or appurtenances for use in, or in connection with, pipes or pipe systems
  • F16L55/26—Pigs or moles, i.e. devices movable in a pipe or conduit with or without self-contained propulsion means
• • H—ELECTRICITY
  • H04—ELECTRIC COMMUNICATION TECHNIQUE
  • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
  • H04N5/00—Details of television systems
  • H04N5/76—Television signal recording
  • H04N5/91—Television signal processing therefor
  • H04N5/92—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback
  • H04N5/9201—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal
  • H04N5/9206—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal
  • H04N5/9207—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal for teletext
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• This invention relates to the production of the FVIII/vWF complex for therapeutical use possessing both the antihaemophilic A activity and Willebrand activity as well as a high degree of purity.
• antihaemophilic A activity is carried by the factor VIII (designated FVIII or VIII:C) which in the physiological state is associated with Willebrand factor (designated vWF or VIIIR:Ag) in form of the complex FVIII/wWF.
• Factor VIII designated FVIII or VIII:C
• Willebrand factor designated vWF or VIIIR:Ag
• antihaemophilic factor A for therapeutical use which are most generally known and commercialized comprise:
• cryoprecipitate which is obtained by thawing of the fresh blood plasma at 4° C.
• cryoprecipitate which is very contaminated with fibrinogen
• concentration of cryoprecipitate is of 5 to 10 international units (I.U.) per ml, while a value of 25 I.U. per ml can be obtained for the concentrate.
• the concentrate possesses the disadvantage of being still strongly contaminated; the complex constitutes less than 10% of the total proteins of the concentrate.
• the product obtained by these different processes consists of procoagulant factor VIII (FVIII:C) alone, therefore not containing said von Willebrand factor (vWF or VIIIR:Ag), such factor being required for people having Willebrand disease and that moreover such factor VIII isolated in this manner is not under its physiological form (which is normally the FVIII/vWF complex) wherein Willebrand factor serves both as transporter and protector of said factor VIII.
• the saline buffers of elution used are generally not capable of dissociating an antigen-antibody bond.
• the process in question is based on the well known principle of immunopurification (Immunoadsorbents in protein purification (E. Ruoslahti Ed., Sc. J. Immunol. 1976 Supplement No 3, pages 1 to 84--Characterization of a monoclonal antibody to human interferon and its use in affinity chromatography, Stenman et al., J. and Immunol. Meth. (1981) 46 p. 337-345).
• immunopurification Immunoadsorbents in protein purification
• factor VIII When its principle is applied in the particular case of factor VIII, it must be noted that the latter behaves in a very specific manner, i.e. it loses irreversibly its procoagulant activity in the elution solutions which are usually employed in immunopurification such as for example glycine hydrochloride, acetate buffer solution of low pH, KSCN and analogous conditions.
• This invention proposes to respect both the procoagulant function of factor VIII and the integrity of the FVIII/wWF complex and its object is consequently a process characterized by including a fixation of the FVIII/vWF complex in physiological medium on a specific monoclonal antibody and releasing said complex by means of a suitable elution medium having no effect on the nature and the functions of such FVIII/vWF complex but able to dissociate the bonds linking the selected monoclonal antibody to the FVIII/vWF complex, thus collecting the latter in a highly purified form.
• the antibody is bound to a solid carrier
• the monoclonal antibody is selected among those to bind the FVIII/vWF complex in physiological medium and then to release such complex in the elution medium, the antibody itself not being denatured and recovering its capacity of fixing the FVIII/wWF complex after its return into the physiological medium thereby permitting repeated purification cycles;
• the antibody responsive to the above definition is a monoclonal antibody derived from a hybridome selected after a series of hybridations of cells of mouse myelome X63 and mouse splenocytes BALB/C immunized with FVIII/vWF complex;
• the elution medium is selected among the alkaline solution having a pH of between 8.5 and 10.5;
• the alkaline solution is selected among the following bases: NaOH, NH 4 OH, ethanolamine, diethanolamine, triethanolamine and the like.
• the antibodies anti-VIIIR:Ag are identified by means of von Willebrand factor (VIIIR:Ag) fixed on titration plate and of anti-mouse immunoglobulines goat antibody (marked by 125 iodine).
• the antibodies anti-VIIIR:Ag identified as mentioned above are coupled to solid particles of the gel type and they are thereafter tested for their ability to bind the FVIII/vWF complex from plasma, resulting in the decrease of the antihaemophilic A and Willebrand activities tested in vitro.
• the antibodies anti-VIIIR:Ag coupled with the solid particles and capable of fixing efficiently the FVIII/vWF complex are tested for their ability to release the FVIII/vWF complex in alkaline medium (pH 8.5 to 10.5); the eluted antihaemophilic A and von Willebrand activities are tested in vitro by the known processes.
• the collected FVIII/vWF complex can be concentrated by a known process of ultrafiltration or aminohexyl-Sepharose chromatography; the process can be completed with a gel filtration step and/or a lyophilization step.
• Splenocytes of BALB/c mouse hyperimmunized with complex FVIII/vWF were fused by means of polyethylene-glycol with cells of mouse myeloma (X63 cell line).
• the hybridomas producing antibodies anti-VIIIR:Ag are selected and the produced antibodies are coupled with solid particles of Sepharose 4B type and tested:
• the monoclonal antibody produced by the hybridoma selected as above is then placed in a suitable proteic medium and coupled with Sepharose 4B (dextrane polymer). A column of 1 liter is then filled with gel coupled with the antibody.
• Sepharose 4B extracte polymer
• the column equilibrated with sodium chloride 0.1M is loaded with 10 liters of plasma at a flow rate of 0.5 liter per hour.
• the column is then washed with 2 liters of sodium chloride 0.1M, then eluted with 2 liters of triethanolamine, 100 mM (pH 9.9).
• the whole of the active product is collected in 1 liter of eluent and contains about 5000 I.U. of factor VIII and of Willebrand factor, i.e. a yield of 50% and a concentration of 5 I.U. per ml. This product contains 100 times less contaminants than the cryoprecipitate and 10 times less than its concentrate.
• the product can be concentrated up to 25 times (125 I.U. per ml) either by ultrafiltration or by aminohexyl-Sepharose chromatography.
• triethanolamine as an elution buffer allows direct lyophilization of the eluted product. This facility also exists if other volatile bases (NH 4 OH, ethanolamine, diethanolamine or analogous compounds) are used.
• the product resulting from the process is particularly suited to restore deficient activities in haemophilia A and von Willebrand patients through intravenous injection of small volume (500 I.U. in 4 ml).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Hematology (AREA)
• General Health & Medical Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Mechanical Engineering (AREA)
• Combustion & Propulsion (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Toxicology (AREA)
• Signal Processing (AREA)
• Multimedia (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Diabetes (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9307917

Family Applications (1)

Country Status (9)

Cited By (8)

Families Citing this family (7)

Citations (1)

• 1984
  • 1984-09-18 FR FR8414480A patent/FR2570276B1/fr not_active Expired
• 1985
  • 1985-09-17 DE DE8585430031T patent/DE3584817D1/de not_active Expired - Lifetime
  • 1985-09-17 AT AT85430031T patent/ATE69955T1/de not_active IP Right Cessation
  • 1985-09-17 WO PCT/FR1985/000250 patent/WO1986001718A1/fr unknown
  • 1985-09-17 ES ES547051A patent/ES8700568A1/es not_active Expired
  • 1985-09-17 JP JP60504092A patent/JPH0649720B2/ja not_active Expired - Lifetime
  • 1985-09-17 CA CA000490954A patent/CA1257211A/fr not_active Expired
  • 1985-09-17 EP EP85430031A patent/EP0179006B1/de not_active Expired - Lifetime
  • 1985-09-18 US US06/777,335 patent/US4670543A/en not_active Expired - Lifetime
• 1993
  • 1993-03-08 JP JP5072978A patent/JPH06102680B2/ja not_active Expired - Lifetime

Patent Citations (1)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events